Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan · Delayed Price · Currency is TWD 77.60
+0.80 (1.04%)
Sep 8, 2026, 12:48 PM CST
Steminent Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.19B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 941.00K | 305.00K | 47.96% |
| Dec 31, 2022 | 636.00K | -1.49M | -70.01% |
| Dec 31, 2021 | 2.12M | -49.35M | -95.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.37B |
| Medigen Biotechnology | 1.27B |
| Savior Lifetec | 1.12B |
| Mycenax Biotech | 815.87M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| UnicoCell Biomed | 22.46M |
| Locus Cell | 19.40M |